Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Deals

Boehringer Ingelheim Joins MTM Vision Consortium to Advance Diabetes Retinopathy Research

Fineline Cube Nov 13, 2024

Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the...

Company Medical Device

J&J MedTech Receives FDA IDE for OTTAVA Robotic Surgical System Trials

Fineline Cube Nov 13, 2024

US-based Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received an...

Company

Zai Lab Ltd Reports 46% YOY Revenue Growth in Q3 2024 Driven by Vygart, Zejula, and Nuzyra

Fineline Cube Nov 13, 2024

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its Q3 2024 financial...

Company

Legend Biotech’s Q3 Revenue Soars 67% YOY Driven by Carvykti Sales

Fineline Cube Nov 13, 2024

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced its financial results for the third quarter...

Company Deals

Canhelp Genomics Partners with Mirxes to Expand Tumor Origin Testing in Southeast Asia

Fineline Cube Nov 13, 2024

Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership...

Company Deals

Vesalius Therapeutics Partners with GSK for Novel Parkinson’s Disease Treatments

Fineline Cube Nov 13, 2024

US-based Vesalius Therapeutics has entered into a strategic agreement with UK pharmaceutical giant GSK plc...

Company Deals

Flare Therapeutics and Roche Enter Strategic Collaboration for Oncology Drug Discovery

Fineline Cube Nov 13, 2024

US-based Flare Therapeutics Inc., a clinical-stage biotech company specializing in cancer therapies through the use...

Company Deals

Schrödinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates

Fineline Cube Nov 13, 2024

New York-based Schrödinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has...

Company Drug

CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of mRNA Vaccine SYS6026

Fineline Cube Nov 13, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...

Policy / Regulatory

NHSA and MoF Announce Medical Insurance Fund Prepayment Initiative to Aid Healthcare Institutions

Fineline Cube Nov 12, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly issued...

Company

InnoCare Pharma Reports 29.8% Revenue Increase in Q3 2024 Financials

Fineline Cube Nov 12, 2024

Beijing-based biotech InnoCare Pharma (HKG: 9969; SHA: 688428) has released its financial report for the...

Company Deals

Triton Partners Mulls Acquisition of Germany’s Evotec SE, Shares Soar 22%

Fineline Cube Nov 12, 2024

Private equity firm Triton Partners is reportedly contemplating the acquisition of Germany-based Evotec SE (NASDAQ:...

Company

GenScript Biotech Expands in Australia with New Sydney Operations and Logistics Center

Fineline Cube Nov 12, 2024

GenScript Biotech Corporation (HKG: 1548), a leading Chinese biotechnology company, has announced the establishment of...

Company Deals

Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies

Fineline Cube Nov 12, 2024

China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A...

Company Deals

Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences

Fineline Cube Nov 12, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its...

Company Drug

Gan & Lee’s GZR18 Shows Significant Weight Loss in Phase IIb Study at ObesityWeek 2024

Fineline Cube Nov 12, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the oral presentation...

Company Drug

J&J’s Nipocalimab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease

Fineline Cube Nov 12, 2024

US-based pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received...

Company Drug

Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Nov 12, 2024

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its US partner argenx SE...

Company Drug

Cutia Therapeutics’ CU-10201 Receives NMPA Approval for Acne Vulgaris Treatment

Fineline Cube Nov 12, 2024

Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced that its CU-10201, a...

Company Drug

BeyondSpring Presents Positive Phase II Data for Plinabulin Combination Therapy in NSCLC at SITC

Fineline Cube Nov 12, 2024

BeyondSpring Inc. (NASDAQ: BYSI), a US-based biotech company, has announced the presentation of the latest...

Posts pagination

1 … 214 215 216 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.